Healthcare & Life Sciences — April 3, 2026

Olympus Thunderbeat II Medical Device Recall

ANSM issued safety alert R2608456 regarding a lot withdrawal of Olympus Thunderbeat II ultrasonic and electric surgical scissors. Olympus notified the agency of a batch recall affecting interior use pharmacies and health establishments in France. Users received direct correspondence with recall instructions. The recall is registered under reference R2608456.

Vue PACS v12 Philips Medical Systems Safety Recall

ANSM reported a safety action by Philips Medical Systems Nederland BV regarding Vue PACS v12. Users have received direct notification from the manufacturer. The safety action is registered under reference R2607071.

Adhese 2 Dental Amalgam Recall, Ivoclar Vivadent AG

ANSM issued safety alert R2609516 regarding a batch recall of Adhese 2 dental amalgam by Ivoclar Vivadent AG. Healthcare facilities, dental centers, and dental surgeons using this product should verify their inventory for affected lots. The company has directly notified impacted users with return instructions.

Joint Commission HHA Accreditation Renewal Request

CMS has published a proposed notice announcing receipt of the Joint Commission's application for continued recognition as a national accrediting organization for home health agencies (HHAs) seeking Medicare or Medicaid participation. The agency is soliciting public comments on this renewal request through May 4, 2026.

ACHC Critical Access Hospital Accreditation Approval

CMS announced continued approval of the Accreditation Commission for Health Care Inc. (ACHC) as a national accrediting organization for Critical Access Hospitals participating in Medicare or Medicaid. The approval period runs for six years, from December 27, 2025 through December 27, 2031.

ACHC Hospice Accreditation Reapproved by CMS

CMS has approved the reapplication of the Accreditation Commission for Health Care Inc. (ACHC) for continued status as a national accrediting organization for hospice programs under Medicare and Medicaid. The approval term runs from November 27, 2025 through November 27, 2031, a standard six-year renewal period. ACHC-accredited hospices will continue to receive deemed status for Medicare participation without requiring separate state agency certification.

Heart Pump Device Correction - Impella RP SmartAssist Sensor Drift

FDA identified a Class I recall of Abiomed Impella RP with SmartAssist and Impella RP Flex with SmartAssist heart pumps due to differential pressure sensor drift causing inaccurate pump flow readings on the Automated Impella Controller. The correction involves updated Instructions for Use requiring clinicians to reference P-level flow rate tables instead of AIC display values. Affected product codes: 0046-0035 and 1000323.

Abiomed Impella Heart Pump Purge Cassette Recall

The FDA issued a Class I recall notice for Abiomed's Generation 1 Impella Purge Cassettes and Impella RP Pump Sets due to an increased risk of purge leaks that may cause pump failure, resulting in patient death. Abiomed has reported four serious injuries and no deaths associated with this issue as of February 3, 2026. Healthcare facilities must immediately identify, quarantine, and return affected Generation 1 devices, transitioning to Generation 2 Purge Cassettes where available.

Intent to Use Trademark Application for SIXTY-ONE SIX ONE

USPTO recorded an Intent to Use trademark application (TM87106087) for SIXTY-ONE SIX ONE (61) filed by SIXTY ONE SIX ONE LLC. The application covers retail store services featuring apparel, toiletries, perfumery, and grooming accessories, as well as men's grooming services including haircuts, styling, shaves, manicures, massages, and facial treatments.

GENETWISTER Trademark Published for Opposition

The USPTO published trademark application TM79412178 for GENETWISTER on April 2, 2026, initiating the opposition period. The application covers software for crop genome analysis, scientific research services in molecular breeding and bioinformatics, and agricultural biotechnology consulting. Third parties have until the opposition deadline to challenge the registration.

KLINIKUR Trademark Application - Class 044 Medical Services

The USPTO published trademark application TM79431105 for KLINIKUR covering medical services (Class 044), cosmetics, pharmaceuticals, medical apparatus, and retail services. The application was filed on March 14, 2025 and published for opposition on April 2, 2026. Any party who believes they would be damaged by the registration of this mark has a 30-day window to file an opposition.

Feeding Futures trademark published for opposition

The USPTO published trademark application TM79424058 for 'Feeding Futures' on April 2, 2026. The trademark covers infant feeding products including breast pumps, feeding bottles, milk storage bags, and related medical services. The publication initiates a standard 30-day opposition period during which third parties may challenge the registration.

POLTX Trademark - Pharmaceutical Antimicrobials and Medical Services

The USPTO published trademark application TM79437237 for POLTX covering pharmaceutical antimicrobials, veterinary preparations, medical devices, and related services in Class 44. The trademark was published on April 2, 2026, initiating a 30-day opposition period during which third parties may challenge the registration. This is a routine trademark prosecution action with no regulatory compliance requirements.

XMEDIX Trademark Application - AI Medical Software SaaS

USPTO published trademark application TM79435153 for XMEDIX covering AI-powered SaaS medical software including LLM-based language processing, medical information analysis, and healthcare chatbots. The trademark covers multiple international classes including software development, medical information services, and downloadable AI applications. Third parties have an opportunity to file an opposition during the statutory period.

ONKOREPLICA Trademark - Oncology Diagnostics

USPTO published trademark application TM79437761 for "ONKOREPLICA" covering medical diagnostic services for oncology using live cell preparations, medical and pharmacological research services using in vitro analysis of cellular responses, and biological preparations containing live cells for scientific research. The trademark covers international class 044 (medical services) and class 001 (chemical preparations).

TCANCER Trademark Application - Cancer Diagnostics and Therapeutics

The USPTO published trademark application TM79437944 for TCANCER covering diagnostic reagents, pharmaceutical preparations, and treatment products for cancer. The application covers chemical reagents for medical diagnosis, diagnostic test kits for cancer detection, and pharmaceutical preparations for cancer treatment and prevention. Third parties have until the opposition deadline to challenge the registration.

Hendrix Genetics Trademark Application for Animal Breeding Services

USPTO published trademark application TM79438416 for HENDRIX GENETICS covering animal breeding services (semen, eggs for animal breeding), biomedical research, and scientific research in genetics. The application was filed October 20, 2025 and published for opposition on April 2, 2026.

FDA Petition Attachment - Content Restricted

FDA received a petition (FDA-2026-P-3664) with restricted attachment content. The document appears to be a regulatory filing submitted to the agency. Specific substance and scope cannot be determined due to copyright restrictions on the attachment.

Tennessee Health Care AI Bill - Prohibition on AI as Mental Health Professional

Tennessee enacted SB 1580 (signed April 1, 2026, effective July 1, 2026) prohibiting AI developers and deployers from advertising AI systems as qualified mental health professionals. Violations constitute unfair or deceptive acts under the Tennessee Consumer Protection Act, subject to civil penalties up to $5,000 per violation and private right of action.

NYBOP May 2026 Deadline Requires Pharmacy and Pharmacist Licensure for Shared Services

The New York State Board of Pharmacy issued guidance in December 2025 requiring individual licensure for pharmacists participating in shared pharmacy services arrangements when servicing New York patients, effective May 22, 2026. Nonresident pharmacy registration alone is no longer sufficient. Pharmacies must identify and license all pharmacists supporting New York operations, including remote personnel, by the May deadline.

CVR pays $4M FCA settlement for unnecessary procedures

Center for Vein Restoration (CVR) Management LLC agreed to pay $4 million to settle False Claims Act allegations that it billed Medicare, Medicaid, and TRICARE for medically unnecessary vein procedures. The settlement resolves two qui tam actions filed in 2015 and 2018, with proceeds distributed among eight state Medicaid programs, DC, the federal government, and the original whistleblowers.

Private Equity Healthcare Impact Analysis

The NYU Stern Center for Business and Human Rights released a report on private equity's expanding role in healthcare, noting over $1 trillion in largely debt-financed transactions over the past decade. The report identifies patterns including elevated debt levels, staffing reductions, and a 25% increase in in-hospital complications following private equity investments. The analysis highlights dividend recapitalizations and sale-leaseback transactions as contributing factors, with private equity-sponsored healthcare entities showing 10X increased insolvency risk.

Greene v. Progressive Corp. - Tobacco Premium Surcharge ERISA Claims Dismissed

The Northern District of Ohio dismissed Greene v. Progressive Corp., a lawsuit challenging tobacco premium surcharges under ERISA. This is the third federal court to hold that employers are not required to provide retroactive reimbursement of premium surcharges when employees complete tobacco cessation courses during a plan year. The court also dismissed breach of fiduciary duty claims, finding the employer acted as a settlor rather than a fiduciary when implementing the wellness program.

AHLA Conference Government Fraud Enforcement Healthcare Analysis

This Morgan Lewis Health Law Scan article covers the American Health Law Association (AHLA) Institute on Medicare and Medicaid Payment Issues conference held March 18-20, 2026 in Baltimore. Government representatives from CMS, HHS OIG, and HHS OGC made presentations on fraud enforcement priorities including the CRUSH (Comprehensive Regulations to Uncover Suspicious Healthcare) rule, Milliman Inc. winning CMS's AI fraud detection competition, and OIG noting $6.8 billion in FCA settlements for FY 2025.

Fourth Circuit Blocks West Virginia 340B Contract Pharmacy Law as Preempted

The Fourth Circuit affirmed a preliminary injunction blocking West Virginia's S.B. 325, which would have restricted how drug manufacturers implement 340B contract pharmacy policies. The court held that the state law is likely preempted because it impermissibly rewrites the federal contractual bargain Congress struck with manufacturers under its spending power. Manufacturers sued over $50,000 per violation penalties.

Group Health Plan Compliance Audit Requirements ERISA ACA

Bradley Arant Boult Cummings LLP published an educational article advising employers on compliance audit requirements for ERISA-covered group health plans. The article identifies key review areas including plan documentation, participant disclosures, Form 5500 reporting, fiduciary governance, and COBRA administration. Employers are encouraged to conduct proactive systematic compliance reviews with legal counsel to reduce legal exposure and prepare for regulatory inquiries.

VYLOY Patent Extension Application Comment Period

FDA opened a 60-day public comment period on a patent term extension application for VYLOY, a drug product. Commenters may submit feedback through regulations.gov regarding this application.

VYLOY Patent Extension Notice Comment

FDA is accepting public comments on a patent term extension notice for VYLOY (cisplatin), a chemotherapy drug. Comments are being submitted through Regulations.gov docket FDA-2025-E-0863. The notice relates to potential patent term extension eligibility under the Drug Price Competition and Patent Term Restoration Act.

VYLOY Regulatory Review Period Patent Extension Comment Form

FDA opened a public comment period on the regulatory review period patent extension for VYLOY (vonoprazan), a potassium-competitive acid blocker approved for gastric acid-related conditions. Comments are being accepted through regulations.gov docket FDA-2025-E-0845. Stakeholders may submit comments on behalf of themselves, organizations, or anonymously.

VYLOY Patent Extension Comment Period

FDA has opened a public comment period on a patent term extension application for VYLOY (citizens乏 details unspecified). Comments on FDA-2025-E-0866-0006 must be submitted by June 2, 2025. This consultation allows interested parties to provide input on the patent extension determination.

ZIIHERA Patent Extension Comment Form

FDA has opened a public comment period on Regulations.gov for a patent extension related to ZIIHERA. The comment form is accessible for submission of feedback by interested parties including pharmaceutical companies, manufacturers, and individuals. The docket number is FDA-2025-E-0372-0005.

Patent Extension Comment Period

FDA has opened a 60-day public comment period for a patent extension matter under docket FDA-2025-E-3074-0006. The agency is seeking stakeholder input on the EMRELIS patent extension proposal. Interested parties may submit comments through Regulations.gov.

Background Material Supporting Proposed Regulatory Action

The FDA published background material supporting docket FDA-2026-P-3665. This document provides supplementary information related to a proposed regulatory action in the pharmaceutical or medical product space. The docket is open for public review and potential comment submission.

EMRELIS Patent Extension Comment Form

FDA has opened a public comment period for EMRELIS patent extension matter via regulations.gov docket FDA-2025-E-3073. The 60-day comment window allows interested parties to submit feedback on the patent term extension application. Commenters may submit as individuals, organizations, or anonymously with attachments up to 10MB.

FDA Acknowledgement of Submission from Hyman Phelps McNamara

FDA CDER issued an acknowledgement letter to Hyman, Phelps & McNamara, P.C. regarding a submission under docket FDA-2026-P-3664-0002. The acknowledgement confirms receipt of the submission but no substantive regulatory action is detailed in the available metadata.

ENFLONSIA Patent Extension Consultation

The FDA is seeking public comments on an ENFLONSIA patent extension application (Docket FDA-2025-E-3626-0006). Comments must be submitted by June 2, 2025 via Regulations.gov. This consultation follows standard FDA procedures for pharmaceutical patent-related matters.

FDA Survey Comment Form

The Food and Drug Administration (FDA) has opened a public comment period on a survey (Docket FDA-2026-N-2740-0001) via regulations.gov. The comment period remains open until June 2, 2026. This is a standard consultation seeking public input on an unspecified FDA survey topic.

VYLOY Patent Extension Comment Period Notice

The FDA has opened a 60-day public comment period for a patent extension application related to the drug VYLOY (zolbetuximab). Pharmaceutical companies and other interested parties may submit comments on the patent term restoration matter. The comment period provides an opportunity for stakeholders to voice concerns or support regarding the extension.

ENCELTO Regulatory Review Period Determination for Patent Extension

The FDA has determined the regulatory review period for ENCELTO, a human biological product, and published this notice as required by law for patent extension purposes. Any person may submit comments on the accuracy of the published dates by June 2, 2026, or petition FDA regarding due diligence by September 30, 2026.

INJECTAFER Regulatory Review Period for Patent Extension

FDA has determined the regulatory review period for INJECTAFER (ferric carboxymaltose injection) for purposes of patent extension under 35 U.S.C. 156. The Agency published this notice as required by law following a patent extension application submitted to the USPTO. Any person with knowledge of incorrect dates may submit comments by June 2, 2026, or petition FDA regarding due diligence by September 30, 2026.

DEA Controlled Substance Prescription Rule Correction

The Drug Enforcement Administration issued a correction to 21 CFR § 1306.07, fixing paragraph letter references in amendatory instruction 15 from '(e)' and '(f)' to '(g)' and '(h)'. This technical correction to the controlled substance prescribing rule affects entities regulated under DEA's multiple prescription provisions.

Technical Amendment to DEA Form 222 Power of Attorney Provisions

DEA issued a final rule correcting 21 CFR 1305.05(c) and (e) to align with the 2019 amendment at 21 CFR 1305.05(d)(1). The technical amendment clarifies that only a registrant, partner, or officer may execute or revoke a DEA Form 222 Power of Attorney, resolving ambiguities from an administrative error. The rule also removes obsolete transition provisions for the triplicate version of DEA Form 222.

3-Methoxyphencyclidine Placed in Schedule I

The Drug Enforcement Administration has issued a final rule placing 3-methoxyphencyclidine (3-MeO-PCP) in Schedule I of the Controlled Substances Act. This action enables the United States to meet its obligations under the 1971 Convention on Psychotropic Substances following the Commission on Narcotic Drugs' Decision 64/4. All persons handling 3-MeO-PCP will be subject to regulatory controls and administrative, civil, and criminal sanctions applicable to Schedule I controlled substances.

Temporary Scheduling of Bromazolam as Schedule I Controlled Substance

The DEA issued a temporary scheduling order placing bromazolam (8-bromo-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine) in Schedule I of the Controlled Substances Act. The order is effective March 16, 2026, and will remain in effect until March 16, 2028. DEA determined that bromazolam poses an imminent hazard to public safety, triggering the temporary scheduling authority under 21 U.S.C. 811(h).

P2P Methyl Glycidic Acid Control as List I Chemical

The Drug Enforcement Administration finalized control of P2P methyl glycidic acid (2-methyl-3-phenyloxirane-2-carboxylic acid, also known as BMK glycidic acid) as a List I chemical under the Controlled Substances Act. This action subjects all handlers of this precursor chemical to CSA regulatory requirements including registration, recordkeeping, and reporting obligations. The rule takes effect May 4, 2026.

Newsletter on Transplantation and Donation Practices

EDQM published a newsletter addressing transplantation and donation practices. The newsletter appears to be an informational communication for healthcare professionals and stakeholders involved in organ donation and transplantation across Europe. Specific content details were inaccessible at the time of this review.

Technetium Tc 99m Albumin Aggregated Injection Revision

USP's Small Molecules 4 Expert Committee has issued a Notice of Intent to Revise the Technetium Tc 99m Albumin Aggregated Injection monograph due to a compliance concern with the Appearance acceptance criterion. Comments with supporting data prompted this action. The proposed revision is targeted for an August 1, 2026 official date and is expected to be published as a Revision Bulletin on July 31, 2026.

Medical Device Variance Renewal - Redhouse Productions

FDA CDRH approved a variance renewal for Redhouse Productions (FDA-2023-V-2753-0004). The variance allows deviation from standard medical device manufacturing requirements under specific conditions. The renewal maintains previously granted flexibilities for the regulated entity.

FDA determines regulatory review period for VYLOY patent extension

The Food and Drug Administration has determined the regulatory review period for VYLOY, a human biological product, and published this notice as required by 35 U.S.C. 156 for patent extension purposes. The determination is part of a batch of regulatory review period notices (dockets FDA-2025-E-0845 through FDA-2025-E-0872). Comments on date accuracy are due June 2, 2026, and petitions regarding due diligence may be filed by September 30, 2026.

VYLOY Patent Extension Regulatory Review Period Determination

The Food and Drug Administration has determined the regulatory review period for VYLOY, a human biological product, for purposes of patent extension under federal law. The notice invites public comments on the accuracy of published dates by June 2, 2026, and allows interested persons to petition FDA regarding due diligence by September 30, 2026. This determination affects patent extension calculations for the branded drug manufacturer.

Variance Application from BF Light Shows, Michigan

FDA CDRH received a variance application from BF Light Shows, a Michigan-based entity, seeking regulatory relief or alternative compliance pathway under FDA electronic product radiation control requirements. The application was filed under docket FDA-2026-V-2878.

FDA complaint, CTP author, posted 3rd Apr

FDA complaint, CTP author, posted 3rd Apr

Determination of Regulatory Review Period for EMRELIS Patent Extension

FDA has determined the regulatory review period for EMRELIS, a human biological product, and published this determination as required by law. The notice allows interested parties to comment on the accuracy of dates and to petition FDA regarding due diligence during the review period.

Complaint Regarding Potential Regulatory Violation

FDA posted a complaint under docket FDA-2026-H-3081-0001 on April 3, 2026. The complaint, authored by CTP (Center for Tobacco Products), relates to a potential regulatory violation. No documents are currently available for review on regulations.gov.

ENFLONSIA Regulatory Review Period Determination

FDA has determined the regulatory review period for ENFLONSIA, a human biological product, as required by 35 U.S.C. 156 for patent extension purposes. The notice invites public comment on whether the published dates are incorrect and allows interested parties to petition FDA regarding the applicant's due diligence during the review period.

VYLOY Patent Extension Regulatory Review Period Determination

The FDA has determined the regulatory review period for VYLOY, a human biological product, and published this notice as required under 35 U.S.C. 156. The notice invites comments on whether any published dates are incorrect by June 2, 2026, and allows interested persons to petition FDA regarding due diligence by September 30, 2026.

Customer Service Satisfaction Surveys - PRA Comment Request

The FDA is seeking public comments on proposed customer service satisfaction surveys under the Paperwork Reduction Act of 1995. The 60-day comment period closes June 2, 2026. This is a routine information collection request; no new burdens are proposed as it involves existing customer service survey collections.

B.I.G. VISION Trademark Application - Ophthalmic and Eyewear Products

USPTO published trademark application TM79332062 for B.I.G. VISION covering ophthalmic microsurgical knives, medical instruments, optical lenses, eyewear, and optometry services. The application was filed December 17, 2021, and is now open for public opposition before registration can proceed.

GEMETRIC Trademark - Ophthalmic Medical Devices and Instruments

The USPTO published trademark application TM79411098 for GEMETRIC covering medical instruments for ophthalmic surgery, intraocular lenses, and related pharmaceutical preparations. The application entered the opposition period on April 2, 2026, allowing third parties to challenge registration. Filing date was October 23, 2024.

MEVI Trademark - Vestibular Implant Medical Instruments

USPTO published trademark application TM79412646 for MEVI covering medical instruments, vestibular implants, and related sensor technology. The application, filed October 17, 2024, was published for opposition on April 2, 2026. Third parties have until May 2, 2026 to file an opposition if they believe the mark would cause confusion with existing trademarks.

SWAN trademark published for medical drip chambers, transfusion sets

The USPTO published the SWAN trademark application (TM79405060) for opposition in International Class 10 covering medical devices including drip chambers, transfusion sets, infusion sets, and related components with luer lock activated valves. The application, filed on July 15, 2024, was published on April 2, 2026, opening a standard 30-day opposition window for third parties.

FDA Complaint Filed with Center for Tobacco Products

FDA Center for Tobacco Products filed a complaint under docket FDA-2026-H-3164-0001. The complaint has been closed for comments, indicating the administrative filing process is complete. No documents are available for public review at this time.

EMRELIS Patent Extension Regulatory Review Period Determination

FDA has determined the regulatory review period for EMRELIS, a human biological product, for purposes of patent extension under federal law. The notice opens a public comment period until June 2, 2026, and allows interested parties to petition FDA regarding the applicant's due diligence by September 30, 2026. This determination affects the calculation of any patent term extension.

FDA Complaint Regarding Tobacco Product Regulations

The FDA Center for Tobacco Products filed a complaint under docket FDA-2026-H-2955-0001. The complaint has been closed for further comments. The specific allegations and parties involved are not publicly viewable as the underlying documents are not available for download on regulations.gov.

FDA reviews patent extension for cancer drug VYLOY

FDA reviews patent extension for cancer drug VYLOY

Tobacco Product Citizen Complaint

FDA Center for Tobacco Products received and closed a citizen complaint (FDA-2026-H-3165) for comments. The complaint is now in closed status with no documents available for public review. No regulatory action or compliance requirements identified.

Determination of Regulatory Review Period for ZIIHERA

FDA has determined the regulatory review period for ZIIHERA, a human biological product, as required by law for patent extension calculations. The notice invites comments on the determination and sets deadlines for challenges. Interested parties may submit comments by June 2, 2026, and petitions regarding due diligence by September 30, 2026.

VYLOY Regulatory Review Period Determination for Patent Extension

The FDA has determined the regulatory review period for VYLOY, a human biological product, as required by law for patent extension purposes. The notice solicits public comments on the accuracy of the published dates and allows interested parties to petition FDA regarding whether the applicant acted with due diligence during the review period. Comments on date accuracy are due June 2, 2026, and due diligence petitions are due September 30, 2026.

Determination of Regulatory Review Period for VYLOY Patent Extension

FDA has determined the regulatory review period for VYLOY, a human biological product, as required by law for patent extension purposes. The Agency is publishing this notice to allow interested parties to comment on the determination or petition for redetermination regarding due diligence. Multiple patent extension applications (FDA-2025-E-0845 through FDA-2025-E-0872) are included in this notice.

VYLOY Patent Extension Regulatory Review Period Determination

FDA has determined the regulatory review period for VYLOY, a human biological product, and is publishing this determination as required by law for patent term extension applications. Interested parties may submit comments on the dates or petition FDA regarding due diligence. Comment deadline is June 2, 2026, and petition deadline is September 30, 2026.

ACHC Critical Access Hospital accreditation approved by CMS

CMS announces continued approval of the Accreditation Commission for Health Care Inc. (ACHC) as a national accrediting organization for critical access hospitals (CAHs) participating in Medicare or Medicaid programs. The approval extends for six years from December 27, 2025, through December 27, 2031, maintaining the deemed status pathway for CAHs.

ACHC Hospice Accreditation Program Reapproved by CMS

CMS has approved the reapplication of Accreditation Commission for Health Care Inc. (ACHC) as a national accrediting organization for hospice programs under Section 1865(a)(1)(A) of the Social Security Act. The approval term runs from November 27, 2025 through November 27, 2031. This allows ACHC-accredited hospices to receive deemed status for Medicare and Medicaid participation in lieu of state survey agency reviews.

Booboo Cooler Trademark - Adhesive Bandages

USPTO published trademark application TM99739851 for "BOOBOO COOLER" covering adhesive bandages in International Class 005 (pharmaceuticals). The application was filed on April 1, 2026, and published for opposition on April 2, 2026, initiating a standard 30-day opposition window during which third parties may challenge the registration.

DR.NRCOCO Trademark Application - Medical Goods Class 005

USPTO published trademark application TM99739653 for DR.NRCOCO covering medical and pharmaceutical goods including disinfectants, iodine, vitamins, dietary supplements, antiseptic wipes, and infant formula in Class 005. The mark was filed April 1, 2026 and published April 2, 2026, initiating a standard 30-day opposition period.

HARDNOX Trademark Application - Protein Beverages and Nutritional Supplements

USPTO published trademark application TM99739632 for HARDNOX covering protein-enriched beverages and nutritional supplements in International Class 005. The application, filed April 1, 2026, indicates intent to use the mark in commerce. Competitors in the protein supplement and nutritional beverage space have a three-month window to file oppositions if they believe the mark creates confusion with existing trademarks.

Firo Labs Trademark - Disposable Pet Pads

USPTO published trademark application TM99739512 for "FIRO LABS" covering disposable housebreaking and house training pads for pets (Class 005). The application, filed April 1, 2026, is classified as Intent-to-Use. Third parties may monitor this application for potential conflicts with existing trademarks.

ISSĒL Intent-to-Use Trademark Application

USPTO received an intent-to-use trademark application for ISSĒL (Serial No. TM99702093) in Class 5 covering medical and cosmetic goods including bandages, antiseptics, antibiotic preparations, and cosmetics. The application was filed on March 13, 2026, under an intent-to-use basis.

ZIORA Intent-to-Use Trademark Application for IVF Biotechnology

USPTO published trademark application TM99693848 for ZIORA filed by a biotech company, covering biochemicals for scientific use, medical devices for in vitro fertilization treatment, and cryopreservation kits. The intent-to-use application was filed March 10, 2026, and published April 2, 2026, initiating the opposition period.

SKIN SOURCE Trademark Application - Intent to Use

USPTO filed trademark application TM98748889 for "SKIN SOURCE" covering nutritional supplements for promoting healthy skin. The application was filed on September 13, 2024, under an intent-to-use basis. This is a routine trademark registration record with no compliance obligations for third parties.

DAYSONA Trademark Application - Nutritional Supplements

The USPTO received a trademark application (TM99739674) for DAYSONA covering nutritional supplements, vitamins, mineral supplements, dietary supplements, probiotic supplements, and amino acid products in Class 5. Filed as an Intent to Use application on April 1, 2026, this establishes priority rights for the applicant in the nutritional supplements market.

METRODORA Intent to Use Trademark - Multisystem Disorder Pharmaceuticals

USPTO received an Intent to Use trademark application TM97023419 from METRODORA for pharmaceutical preparations in Class 5 covering treatments for complex or rare multisystem disorders. The application includes pharmaceuticals for conditions such as autoimmune disorders, neurological disorders, gastrointestinal disorders, and pain management. No regulatory obligations or compliance deadlines are associated with this trademark filing.

SALIOGASE Trademark Application

USPTO received trademark application TM90517616 for SALIOGASE under Class 005 (Pharmaceuticals). The application, filed as Intent to Use, covers pharmaceutical preparations for treating genetically driven, neurological, gastrointestinal, metabolic, immunological, oncological, and other specified disorders. Related goods include scientific reagents, nucleic acids, and nucleotides for research and medical purposes.

Desavo Trademark Application - Sanitizing Wipes

USPTO received trademark application TM90514865 for DESAVO (intent-to-use basis) covering sanitizing wipes and hand-sanitizing preparations, filed February 5, 2021. The application remains pending. Third parties have an opportunity to review and potentially oppose the registration within the prescribed period.

Ambrx Trademark Application - Cancer Bio-therapeutics

USPTO published Ambrx's Intent to Use trademark application (TM90487620) for biological and biochemical preparations used in cancer treatment. The application covers protein expression systems for generating novel bio-therapeutics, including bio-conjugated peptides, therapeutic proteins, monoclonal antibodies, and bi/multi-specific medicines. This Class 005 pharmaceutical trademark was filed on January 25, 2021.

HIPAA Compliance in Healthcare Analytics Podcast

Roetzel & Andress law firm published a podcast episode discussing HIPAA compliance considerations for healthcare providers using health analytics. Ericka Adler and Christina Kuta cover how patient data is collected through digital tools and when such data constitutes protected health information.

DEA Designates P2P Methyl Glycidic Acid as List I Chemical

The Drug Enforcement Administration has finalized the designation of P2P methyl glycidic acid (2-methyl-3-phenyloxirane-2-carboxylic acid) and its esters, isomers, and salts as a List I chemical under the Controlled Substances Act, effective May 4, 2026. This chemical is used in the illicit manufacture of phenylacetone, methamphetamine, and amphetamine. All handlers must obtain DEA registration and comply with CSA regulatory provisions, including transaction reporting and recordkeeping requirements.

CDC DELTA Cooperative Agreement Public Comment

CDC has opened a 52-day public comment period for the DELTA Cooperative Agreement (Docket CDC-2026-0364-0001) on Regulations.gov. The comment form allows individuals and organizations to submit feedback on the proposed cooperative agreement. Comments may be submitted as individuals, organizations, or anonymously.

WHO Global Consultation on Public Health and Social Measures for Health Emergencies

The World Health Organization convened its third global technical consultation on Public Health and Social Measures (PHSM) with over 120 experts from 44 Member States on 24-26 March 2026. The consultation advanced work on PHSM Decision Navigator tools, epidemic influenza modules, and community-centred implementation approaches, responding to World Health Assembly Resolution 78.3 on strengthening the evidence base for PHSM.

WHO SAGE Meeting Immunization Progress Challenges Ahead

WHO published Director Kate O'Brien's March 2026 message summarizing the Strategic Advisory Group of Experts on Immunization (SAGE) meeting discussions. The advisory highlighted that immunization has saved over 150 million lives in 50 years while noting that nearly 20 million children missed at least one vaccine dose in 2024. Discussions addressed COVID-19 vaccination guidance, typhoid vaccination strategies, polio eradication, and the path beyond Immunization Agenda 2030.

Urban Health Leaders Renew Commitment to Accelerate Life-Saving Action in Cities

The World Health Organization, Bloomberg Philanthropies, Vital Strategies, and the Municipal Health Secretariat of Rio de Janeiro co-hosted the 2026 Partnership for Healthy Cities Summit in Rio de Janeiro, bringing together health officials from 55 cities. Baltimore, USA announced it will join the Partnership to focus on overdose prevention. Cities showcased initiatives including tobacco control, healthy school food environments, and heat health action protocols.

Updated Opioid Dependence Treatment and Overdose Prevention Guidelines

WHO announced updates to guidelines for opioid dependence treatment and overdose prevention, including new conditional recommendations for long-acting injectable buprenorphine alongside continued strong recommendations for methadone and oral buprenorphine. The full guidelines are expected later in 2026 or early 2027. Currently, fewer than 10% of approximately 64 million people worldwide with drug use disorders receive treatment.

CTP Complaint Against Tobacco Product Company

The FDA Center for Tobacco Products filed and closed a complaint (FDA-2026-H-3163-0001) on April 3, 2026. The specific allegations, respondent identity, and resolution details are contained in the attached complaint document. This represents routine enforcement activity under FDA's tobacco product authority.

ZIIHERA Regulatory Review Period Determination for Patent Extension

FDA has determined the regulatory review period for ZIIHERA, a human biological product, as required by law for patent extension applications. The notice publishes these dates and provides timelines for public comments and petitions. Comments on date accuracy are due June 2, 2026, and petitions regarding due diligence are due September 30, 2026.

EMRELIS Regulatory Review Period Determination for Patent Extension

FDA has determined the regulatory review period for EMRELIS, a human biological product, and published this notice as required by law for patent extension purposes under 35 U.S.C. 156. The determination affects the patent term extension calculation for the product's New Drug Application submitted to USPTO.

ENFLONSIA Patent Extension Regulatory Review Period Determination

FDA published a notice determining the regulatory review period for ENFLONSIA, a human biological product, for purposes of patent extension under 35 U.S.C. 156. The notice allows interested parties to comment on the accuracy of published dates by June 2, 2026, and to petition FDA regarding the applicant's due diligence by September 30, 2026. Docket No. FDA-2025-E-3626.

FDA patent extension review, Injectafer, ends Sep 30

FDA patent extension review, Injectafer, ends Sep 30

Vyloy Patent Extension Regulatory Review Period Determination

FDA has determined the regulatory review period for VYLOY, a human biological product, and published this notice as required by law. The determination is relevant to patent extension applications submitted to USPTO. Interested parties may submit comments by June 2, 2026, or petition FDA regarding due diligence by September 30, 2026.

Oral Rabies Vaccination Program Resuming for Western NC Raccoons

NCDHHS and USDA Wildlife Services are resuming the oral rabies vaccination program for wild raccoons in western North Carolina. The program was postponed from October 2025 due to the federal government shutdown. Bait distribution runs April 8-25, 2026, covering 16 western NC counties to prevent raccoon rabies from spreading west of the Appalachian Mountains.

Vaccine Education Advisory Workgroup Second Meeting Statement

Pennsylvania Secretary of Health Dr. Debra Bogen issued a statement following the second meeting of the state's Vaccine Education Advisory Workgroup. The workgroup, established by Governor Josh Shapiro's Executive Order 2025-02, brings together medical experts and community leaders to provide evidence-based vaccine information and identify barriers to vaccine access. The initiative targets populations at higher risk for diseases like measles and hepatitis B.

Oral Cancer Awareness and Prevention

The Mississippi State Department of Health issued a public health awareness notice recognizing Oropharyngeal, Head and Neck Cancer Prevention Month. The notice provides Mississippi-specific statistics showing approximately 560 diagnoses and 140 deaths annually (25% mortality rate), and identifies tobacco, alcohol, and HPV as primary risk factors.

HHS Reorganization Removing Office of Chief Information Officer

The Department of Health and Human Services published a notice announcing the reorganization of its administrative structure, specifically removing the Office of Chief Information Officer from the organizational chart. The change is effective upon publication date. This is an internal administrative restructuring that affects the agency's chain of command and information technology governance.

ACHC Medicare Hospice Accreditation Program CMS Approval

CMS published notice of approval for the Accreditation Commission for Health Care Inc. (ACHC) to continue its CMS-approved hospice accreditation program. The decision applies from November 27, 2025, through November 27, 2031. This routine approval allows ACHC to continue conducting accreditation surveys for Medicare and Medicaid-participating hospice providers.

ACHC Critical Access Hospital Accreditation Program Continued Approval

CMS published notice of the Accreditation Commission for Health Care Inc. (ACHC) application for continued approval of its Critical Access Hospital accreditation program under Medicare. The decision, if granted, would be effective from December 27, 2025, through December 27, 2031. This notice informs the public of the application and CMS's review process.

Joint Commission Home Health Agency Accreditation Program Renewal Application

CMS published a notice seeking public comments on the Joint Commission's application for continued CMS approval of its Home Health Agency accreditation program. The Joint Commission currently holds deeming authority for Medicare and Medicaid-participating home health agencies. Comments on this accreditation renewal application must be submitted by May 4, 2026.

9th Biennial Minority Health Summit - Heart Health in Minority Communities

The Arkansas Department of Health Minority Health Commission announced the 9th Biennial Minority Health Summit scheduled for April 17, 2026, at the North Little Rock Event Center. The event, themed 'A Bridge to Care: A Multidisciplinary Approach to Heart Health in Minority Arkansans,' commemorates National Minority Health Month and the commission's 35th anniversary. Both in-person and livestream registration options are available.

Human Antibodies With Anti-Lymphocyte Specificities - Licensing Availability

NIH/NIAID issued a notice announcing availability for licensing of novel human IgM antibodies (HHS Ref No. E-025-2025) developed for treating B-cell cancers and autoimmune conditions. The antibodies demonstrated effective B-cell killing at concentrations as low as 0.01 nanomolar. Inventors Dr. Ainhoa Pérez-Díez and Dr. Irini Sereti developed this technology. Companies may contact Benjamin Hurley at 240-276-5489 to pursue licensing.

NIH Center Scientific Review Closed Meetings

The National Institutes of Health Center for Scientific Review announced five closed meetings scheduled for late April 2026 to review grant applications. The meetings will address research in aging, oral/dental sciences, genetic therapies, training programs, and mental health/Alzheimer's disease interventions. Meetings are closed under Federal Advisory Committee Act exemptions to protect confidential grant information and applicant privacy.

Center for Scientific Review Amends Meeting Notice

The NIH Center for Scientific Review issued an amended meeting notice changing the dates for the Neuromodulation and Imaging of Neuronal Circuits Study Section from April 16-17, 2026 to July 9-10, 2026. The meeting remains closed to the public. This is an administrative correction to a previously published Federal Register notice.

Board of Scientific Counselors, NIDA - Notice of Closed Meeting

The National Institutes of Health published a notice announcing a closed meeting of the Board of Scientific Counselors, NIDA, scheduled for May 12, 2026. The virtual meeting will review and evaluate personnel qualifications, performance, and competence of individual investigators under the Federal Advisory Committee Act. The meeting is closed pursuant to 5 U.S.C. 552b(c)(6) to protect personal privacy.

Determination of Regulatory Review Period for INJECTAFER Patent Extension

FDA has determined the regulatory review period for INJECTAFER (ferric carboxymaltose injection) and published this notice as required by law. The determination is needed for the USPTO to calculate patent term extension under the Hatch-Waxman Act. Comments on the calculation may be submitted by June 2, 2026; petitions regarding due diligence may be filed by September 30, 2026.

Customer Service Satisfaction Survey Collection

The FDA is seeking public comments on a proposed information collection for customer service satisfaction surveys. Under the Paperwork Reduction Act of 1995, federal agencies must publish notice and allow 60 days for public comment on proposed collections. Comments are due by June 2, 2026.

Determination of Regulatory Review Period for HYMPAVZI Patent Extension

The FDA has determined the regulatory review period for HYMPAVZI, a human biological product, and published this notice as required by law. The determination was made in connection with an application to the USPTO for extension of a patent claiming the product. Interested parties may submit comments or petitions regarding the determination.

Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS

The FDA has determined the regulatory review period for EMRELIS, a human biological product, and published this notice as required by law for patent extension purposes. The determination affects the calculation of patent term extension under federal law. Comments on the determination may be submitted until June 2, 2026, and petitions regarding due diligence may be filed until September 30, 2026.

Determination of Regulatory Review Period for Patent Extension; ENFLONSIA

The FDA has determined the regulatory review period for ENFLONSIA, a human biological product, and published this notice as required by 21 CFR Part 60. The notice allows any person to submit comments correcting dates by June 2, 2026, and any interested party may petition FDA by September 30, 2026 regarding due diligence during the review period.

Determination of Regulatory Review Period for VYLOY Patent Extension

The FDA has determined the regulatory review period for VYLOY, a human biological product, for patent extension purposes. The Agency is publishing this notice as required by law due to patent extension applications submitted to the USPTO. Comments regarding date corrections must be submitted by June 2, 2026, and petitions for due diligence determinations may be filed by September 30, 2026.

Determination of Regulatory Review Period for ENCELTO Patent Extension

The FDA has determined the regulatory review period for ENCELTO, a human biological product, and published this notice as required by law for patent extension purposes under 35 U.S.C. 156. The determination opens a public comment period through June 2, 2026, and allows petitions regarding due diligence through September 30, 2026.

ZIIHERA Regulatory Review Period Determination for Patent Extension

The FDA has determined the regulatory review period for ZIIHERA, a human biological product, and is publishing this notice as required by law for patent extension purposes under 21 USC 356. The determination is being forwarded to the USPTO for use in processing the patent extension application. Interested parties may submit comments on the accuracy of published dates or petition FDA regarding due diligence during the review period.

TREE OF RECOVERY Trademark Registration Cancelled

The USPTO cancelled trademark registration TM79212665 for TREE OF RECOVERY on April 2, 2026. The registration covered medical devices including wearable activity trackers, health monitoring sensors, and medical diagnostic apparatus, as well as medical services. This cancellation eliminates trademark protection for the mark in International Class 044 (Medical Services).

Langer Medical Trademark Application - Medical Devices and Services

USPTO published Langer Medical's trademark application TM79420210 for opposition. The application covers medical devices including surgical monitoring computers, neurophysiological monitoring equipment, and patient stimulation probes, along with medical services including intraoperative neuromonitoring. The trademark excludes orthotic and orthopedic solutions.

AIDACARE HEALTHCARE EQUIPMENT Trademark Cancelled

The USPTO cancelled Trademark Registration No. TM79212934 for AIDACARE HEALTHCARE EQUIPMENT on April 2, 2026. The registration covered medical apparatus, rehabilitation equipment, healthcare services, and retail store services for medical equipment and invalid aids. Cancellation removes all trademark protections and rights previously associated with this registration.

CALCSHIFT Intent-to-Use Trademark Application - Surgical Implants Class 10

USPTO received an Intent-to-Use trademark application (TM90638142) for CALCSHIFT covering surgical implants, bone fixation devices for foot and ankle, and associated surgical instruments in International Class 10. The applicant filed April 12, 2021, claiming priority from April 2, 2026. No substantive regulatory obligations are created by this filing.

Medical inhaler trademark application - Class 10

USPTO received trademark application TM99739865 for medical inhalation apparatus filed on intent-to-use basis. The application covers Class 10 medical devices including empty inhalers and pre-filled pharmaceutical inhalers for asthma and COPD treatment.

Measles Outbreak Response - Early MMR Vaccination for Infants

MDHHS issued health guidance recommending early MMR vaccination for infants ages 6-11 months in seven Michigan counties due to possible community measles transmission. Eight measles cases have been identified in Washtenaw and Monroe counties. The early vaccination recommendation remains in effect until May 16, 2026.

Federal AI Framework and Trump America Act Healthcare Analysis

The Trump administration released its National Policy Framework for Artificial Intelligence (March 20, 2026) outlining seven legislative priorities including federal preemption of state AI laws and intellectual property protections. Senator Marsha Blackburn introduced a discussion draft of the Trump America AI Act, which would codify Executive Order 14179 and establish a single federal rulebook for AI governance. Both proposals would introduce new liability frameworks, mandatory bias audits, copyright-based training data requirements, and transparency obligations affecting health care and life sciences organizations using AI applications.

Oziltus Biosimilar to XGEVA Approved for Bone Metastases and Multiple Myeloma

FDA approved Oziltus (denosumab-mobz), a biosimilar referencing XGEVA (denosumab), for prevention of skeletal-related events in patients with multiple myeloma and bone metastases from solid tumors. The drug is also approved for giant cell tumor of bone and hypercalcemia of malignancy. Marketed by Amneal Pharmaceuticals LLC, this approval expands treatment options for bone-related oncology conditions.

Boncresa biosimilar to Prolia approved for osteoporosis

FDA approved Boncresa (denosumab-b00) as a biosimilar to Prolia (denosumab), providing a new treatment option for patients with osteoporosis. The product is indicated for postmenopausal women, men, and patients with glucocorticoid-induced osteoporosis at high risk for fracture, as well as bone loss from hormone ablation therapy for cancer. Boncresa is administered as a 60 mg subcutaneous injection every 6 months.

Method and Apparatus for Ablating a Target Volume

The USPTO published patent application US20260090837A1 for a method and apparatus supporting ablation of a target volume in medical procedures. The invention describes a control circuit that registers three-dimensional patient imaging with ablation zone information to generate two-dimensional coverage representations. Inventors include Hojjatollah Fallahi, Dane Olson, and Gael Luis Boivin.

Shunting Catheters and Methods for Tisusal Removal

The USPTO published patent application US20260090834A1 for shunting catheters and tissue removal methods. The application (No. 18899694) was filed September 27, 2024 and names inventors Rani Abdullah Mahmoudi, Ajay Kumar Dass, and Wei Gan. The invention relates to catheter systems with tissue-removal assemblies for creating shunts in patients.

Minimally Invasive Access Channels Into Bodily Regions

USPTO published patent application US20260090836A1 filed by MicroCube, LLC for access devices and methods to create channels for introducing working devices into anatomical regions. The invention uses visualization modalities (endoscopes, ultrasound) to create access channels that are then used for diagnostic, therapeutic, or preventive procedures, with endometrial ablation as a specific example application.

Patient-specific 3D Surgical Simulation Method and Device

The USPTO published patent application US20260090838A1 by HUTOM Inc. for a patient-specific 3D surgical simulation method, device, and program. The invention covers acquiring patient scan images, generating 3D models of surgical areas with adjacent organs and blood vessels, modeling surgical equipment with environmental variables, and providing patient-specific surgical simulations. The application was filed December 2, 2024 and published April 2, 2026.

Pre-Surgical Analysis System and Methods

USPTO published patent application US20260090839A1 by Prem Ramkumar MD, Inc. for a pre-surgical analytical system that uses CT scan images to predict surgical outcomes. The system classifies and segments anatomical landmarks, calculates angles and measurements against predetermined thresholds, and generates weighted scores indicating potential surgical results. This published application does not create immediate regulatory obligations.

Hip fracture fixation system, patent US20260090830A1, published 2nd Apr

Hip fracture fixation system, patent US20260090830A1, published 2nd Apr

Expandable Veterinary Orthopedic Implant System

The USPTO published patent application US20260090831A1 by IN LIFE VET SA covering an expandable veterinary orthopedic implant system and manufacturing process. The application describes an implant with flanges that expands via support arm pivoting when distal and proximal ends are brought together, with an expansion sleeve mechanism enabling controlled deployment. Filed September 25, 2025.

Calibration Block for Surgical Fiducial Marker Arrays

USPTO published patent application US20260090832A1 for a calibration block designed for surgical fiducial marker arrays. The invention includes a main body with top and side faces, surgical fiducial markers in an asymmetrical arrangement, and screw openings for calibration purposes. Inventors include Jesse Harrison Gallant, Osamah Choudhry, Christopher Morley, and Florentin Jonas Liebmann. Filing date was September 29, 2024, under application number 18900842.

Tissue sealing instrument patent with dual sealing electrodes

The USPTO published patent application US20260090833A1 for a tissue sealing instrument with dual sealing electrodes. The invention features two jaws with sealing electrodes, where one jaw includes a cutting electrode held in a flexible plastic body within a narrow groove, while the opposing jaw contains an elastic counter support seated in a wider recess. Inventors include Volker Mayer, Rolf Weiler, and colleagues. Filing date was September 19, 2025.

Elagolix dosing regimens for GnRH receptor antagonists

USPTO published patent application US20260091036A1 for dosing regimens of Elagolix (a GnRH receptor antagonist) and related compounds. The application claims methods to minimize bone mineral density changes in subjects suffering from endometriosis, adenomyosis, PCOS, or uterine fibroids. Filing date August 26, 2025.

PFIC Treatment Methods Using IBAT Inhibitor Odevixibat

USPTO published patent application US20260091040A1 for methods of treating progressive familial intrahepatic cholestasis (PFIC) using IBAT inhibitor odevixibat. Inventors include Per-Göran Gillberg, Jan Mattsson, Pat Horn, and Paresh Soni. The application covers reducing pruritus scores, serum bile acid concentration, improving liver parameters, height normalization, weight improvement, and sleep quality.

Methods of Treating Heavy Menstrual Bleeding

USPTO published patent application US20260091041A1 for methods of treating heavy menstrual bleeding with or without uterine fibroids. The application claims a method using compound 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or salts thereof in combination with estrogens and progestogens. Fifteen inventors are named including Kristof Chwalisz, Jane Castelli-Haley, and others.

Compositions and Methods for Treating Mycobacterium Infections

USPTO published patent application US20260091043A1 for compositions and methods treating infections caused by Mycobacteriaceae family pathogens, including those causing tuberculosis. Inventors John David Wild, Jeremy Joseph Yang, and Sean Ekins filed the application on September 20, 2023. The application claims priority to Application No. 19113756 and covers novel therapeutic approaches to bacterial infections.

Aqueous Pharmaceutical Formulation of Hydrocortisone Sodium Phosphate and Monothioglycerol

The USPTO published patent application US20260091042A1 filed by Antares Pharma, Inc. (inventors Xiaoming Chen, Shaowei Ong) covering aqueous pharmaceutical formulations comprising hydrocortisone sodium phosphate and monothioglycerol as an antioxidant, with optional buffer components including monobasic/dibasic sodium phosphate or disodium EDTA. The application also discloses methods of treating diseases or disorders by administering the formulation. This is routine intellectual property protection activity for a pharmaceutical formulation invention.

Carbasalate Calcium Application for Hydrocephalus Treatment

The USPTO published patent application US20260091044A1 by Tianjin University covering the use of carbasalate calcium as the sole or primary active ingredient for treating hydrocephalus. The application includes zebrafish model experimental data demonstrating significant reduction in fourth ventricle area and improvements in swimming metrics. No regulatory compliance deadlines or penalties apply to this patent application publication.

Doxycycline Mouthwash for COVID-19 Prevention

USPTO published patent application US20260091045A1 for a preventative mouthwash containing doxycycline (100-400mg dosage) for COVID-19 infection prevention. Inventor Bruce Roseman's application describes a gargling method using 5-20mL of the mouthwash twice daily for 5-10 days. The application was filed October 2, 2024 and published April 2, 2026.

Sepiapterin Methods for BH4 Disorders

USPTO published patent application US20260091037A1 for sepiapterin compositions and methods treating BH4-related disorders. Inventors Neil Smith and Jonathan Reis filed the application on May 13, 2025. The application covers methods for increasing sepiapterin plasma, CSF, and brain exposure for therapeutic use.

Kona Low Environmental Monitoring Finds E. coli and Salmonella in Floodwater

The Hawaii Department of Health released preliminary environmental monitoring results from the Kona Low storm recovery. Samples collected from floodwater, mud, and sediment at four sites detected E. coli, Enterococcus, and Salmonella bacteria. Hepatitis A was not detected. Testing for additional pathogens including Staphylococcus aureus, Campylobacter, Clostridium perfringens, Clostridium tetani, and Leptospira is still pending. The DOH confirms existing precautions remain appropriate.

RAW FARM Raw Milk Cheddar Cheese Recall - E. coli O157:H7

The Hawaii Department of Health issued an alert regarding a RAW FARM recall of Raw Milk Cheddar Cheese products due to potential E. coli O157:H7 contamination. Seven products are affected, including shredded and block varieties in various sizes with expiration dates through September 2026. Nine illnesses have been reported nationally linked to these products.

Colon Cancer Screening Campaign for Adults 45 and Older

The Hawai'i Department of Health launched the 'Get Screened Hawai'i' public awareness campaign in April 2026 to encourage colorectal cancer screening for adults starting at age 45. The campaign runs through June 2026 across TV, radio, digital, and print media, directing residents to GetScreened.hawaii.gov. Approximately 700 Hawai'i adults are diagnosed with and 225 die from colon cancer annually.

Annette Mente - AMCHP Leadership Award Recipient

The Hawaii Department of Health announced Annette Mente as the 2026 recipient of the AMCHP Excellence in State Maternal and Child Health Leadership Award. The award recognizes her more than 25 years of leadership in strengthening Hawaii's maternal and child health system, including her role as FHSD Title V planner and health equity initiatives.

Ultrasound endoscope access device pierces hollow organs

The USPTO published patent application US20260090824A1 by Olympus Corporation covering a treatment method and device with an ultrasound endoscope access device. The invention includes an access pipe insertable into an endoscope sheath, a piercer for puncturing hollow organs through the digestive tract, and a switchable configuration system that turns the piercing function on or off. The application was filed on December 9, 2025, with six inventors including Tomotaka Hayakawa and Tomofumi Katayama.

Ultrasonic surgical instrument, mechanical harmonic generator, Apr 02

Ultrasonic surgical instrument, mechanical harmonic generator, Apr 02

Selectable Angle Needle Guide for use with Imaging Probes

USPTO published patent application US20260090822A1 for David Kinas' selectable angle needle guide assembly for use with ultrasound or similar imaging probes. The invention features a body section engaging the probe head with parallel leg members forming a channel sized for needle insertion into patient tissue under visual observation. This is a routine patent publication notice with no new regulatory requirements.

Expandable Intravascular Catheter with Controlled Strut Expansion

USPTO published patent application US20260090821A1 for an expandable intravascular catheter with controllably movable struts. The device allows the expandable portion to move between expanded and contracted positions relative to the catheter tube's outer diameter. Inventors: John P. Pigott, Jenny Zeroni, Adam Tschida. Application filed October 7, 2025.

Biopsy Needle Position Detection Method and Device

USPTO published patent application US20260090823A1 for Siemens Healthineers AG covering an automated method and device for determining the position of a biopsy needle tip using sensor technology. The system calculates the distance from the needle tip to a reference point during biopsy procedures. Medical device manufacturers and healthcare providers should monitor this filing for potential IP considerations in related technologies.

Intraluminal Puncturing Catheter System

USPTO published patent application US20260090825A1 by REVASCARDIO LTD. for an intraluminal puncturing catheter system. The invention includes a catheter with a flexible positioning arm, a second catheter with opened distal end, and a tissue puncturer extendable through the system. The technology is classified under CPC A61B 17/3417 and related categories for diagnosis and surgical instruments.

Bunion Correction Clamp Assembly Patent Application

USPTO published patent application US20260090826A1 for a bunion correction clamp assembly. The invention by inventors Amiot and Flagle describes a surgical device with an elongate bridge, sliding/rotating blocks, and pins for positioning bone segments during foot surgery. The application was filed November 26, 2025 under Application No. 19401964.

Orthopedic External Fixator Pin Clamp

USPTO published patent application US20260090827A1 for an orthopedic external fixator pin clamp device filed by New Standard Device, LLC. The application claims an orthopedic clamp comprising upper and lower clamp portions with a flexible hinge and shaft hole for attachment to an orthopedic strut. The application was filed on February 19, 2025, with five named inventors including Robert E. Wigginton and Thomas L. Hand.

Robot Assisted Rod Bending Surgical Patent

The USPTO published patent application US20260090828A1 for a robot-assisted surgical rod bending method invented by Eric Finley and Thomas Scholl. The invention captures poses of surgical tools coupled to robotic devices and determines implant positions to generate bend curves and bending instructions for surgical linking devices. Medical device manufacturers developing surgical robotics should review this publication for competitive intelligence and freedom-to-operate considerations.

Veterinary orthopedic instruments for expandable bone implants

The USPTO published patent application US20260090829A1 filed by IN LIFE VET SA for veterinary orthopedic instruments designed to implant expandable bone implants. The invention includes a main grippable body, an implant-holding portion with retention means, and a fluid injection instrument for deploying the implant. No compliance deadlines or regulatory requirements are associated with this publication notice.

Methods of Treating Inflammatory Diseases with Formula I and II Compounds

The USPTO published patent application US20260091026A1 covering compounds of Formula (I) and Formula (II), and their use in treating inflammatory diseases. The application was filed December 5, 2025, and published April 2, 2026, naming inventors Robert Joseph Moreau, Naomi S. Rajapaksa, David C. Tully, and others. The claimed subject matter includes novel compounds, pharmaceutical compositions, and methods of treatment for inflammatory diseases and disorders.

Amorphous Solid Dispersions Patent - Intra-Cellular Therapies

USPTO published patent application US20260091032A1 by Intra-Cellular Therapies, Inc. for stable amorphous solid dispersions of a quinoxaline-derived compound with potential applications in neurological and metabolic disorders. The application, filed August 6, 2025, contains 29 CPC classifications spanning formulations, compounds, and therapeutic indications.

CGRP Receptor Antagonists for Treating Chemotherapy-Induced Nausea and Vomiting

The USPTO published patent application US20260091031A1 by inventor Alberto Chiarugi covering a method of using CGRP receptor antagonists (gepants) for treating chemotherapy-induced nausea and vomiting (CINV). The application claims the use of these migraine-approved drugs to target CGRP neuropeptides to prevent and counteract drug-induced nausea including CINV.

HIGH-DOSE NALOXONE FORMULATION

The USPTO published patent application US20260091030A1 for high-dose Naloxone formulations designed to treat ultra-potent synthetic opioid overdose. Invented by Gita Shankar and Suresh Potharaju, the formulation comprises naloxone hydrochloride with preservatives, buffering agents, and tonicity modifiers. The application was filed September 1, 2023, and published April 2, 2026.

Pridopidine for ALS Treatment

USPTO published patent application US20260091028A1 by Prilenia Neurotherapeutics Ltd. for a method of treating amyotrophic lateral sclerosis (ALS) using pridopidine. The application claims therapeutic use of pridopidine or a pharmaceutically acceptable salt for human subjects afflicted with ALS. Application No. 19391284 was filed on 2025-11-17.

Stilbene Derivatives as AHR Regulators with Improved Photostability

The USPTO published patent application US20260091027A1 for stilbene derivatives serving as aryl hydrocarbon receptor (AHR) regulators with improved photostability over the marketed drug Benvitimod. The application, filed September 19, 2023 under Application No. 19113670, covers compounds of formula I-1, their stereoisomers, salts, and prodrugs, along with preparation methods for gram-to-kilogram scale synthesis.

Modified Release Minoxidil Compositions and Methods for Oral Administration

The USPTO published patent application US20260091035A1 by inventor Reid Waldman covering modified release minoxidil pharmaceutical formulations for oral daily dosing to treat hair loss. The application claims compositions including slow modified release vehicles containing minoxidil or pharmaceutically acceptable salts, optionally combined with additional active agents. Filing date was December 9, 2025.

Modified Release Minoxidil for Hair Loss Treatment

The USPTO published patent application US20260091034A1 by inventor Reid Waldman for a modified release oral formulation of minoxidil for treating hair loss. The application discloses pharmaceutical compositions including daily doses of modified release minoxidil, potentially combined with additional active agents, delivered via a slow release vehicle. The filing date is December 4, 2025, with publication on April 2, 2026.

FGFR3 Antagonist for Skeletal Disorders Treatment

The USPTO published patent application US20260091033A1 for an FGFR3 antagonist for treating skeletal disorders linked to abnormal FGFR3 activation. The application, filed by inventors LEGEAI-MALLET, MUNNICH, BUSCA, and BARBAULT on January 15, 2025, covers compositions and methods for treatment. This publication represents a new patent application and creates no immediate compliance obligations for industry.

Markers for the Diagnosis of Biochemical Recurrence in Prostate Cancer

USPTO published patent application US20260092922A1 for biomarkers and diagnostic methods related to prostate cancer biochemical recurrence (BCR). The application (No. 19207308, filed May 13, 2025) includes 9 inventors and covers methods for detecting BCR biomarkers, compositions, and diagnostic kits. This is a routine patent publication with no new regulatory requirements.

AneurysmFlow Medical Device Recall - Unreliable mafa Ratio

Health Canada issued a Type II recall for AneurysmFlow software (Model 1.4) manufactured by Philips Medical Systems Nederland B.V. The recall addresses unreliable mafa ratio measurements that provide inaccurate prognostic information for aneurysm occlusion following flow diverter stent treatment. Despite existing cautions in the instructions for use, the displayed mafa ratio may still influence intraprocedural clinical decisions, potentially resulting in incorrect patient treatment choices.

Olympus Connecting Tubes Premature Failure Recall

Health Canada issued a Type II medical device recall for Olympus Medical Systems Corp. connecting tubes (models MAJ-2110 through MAJ-2330) due to premature failure where lock levers detach or break earlier than expected in Version 2 products. Olympus will remove prior versions from the market and replace them with the current design. Affected parties should identify, quarantine, and contact the manufacturer for replacement.

Aved Products Recall - Unauthorized Ophthalmic Solutions

Health Canada issued a Type III recall for Aved ophthalmic solutions from Labtician Ophthalmics, Inc. Nine products were sold without market authorization (DIN) in Canada due to third-party branding issues. Affected products include various atropine sulfate solutions (0.01%-0.05%), fluorescein/proparacaine, insulin ophthalmic, mitomycin, moxifloxacin, and combination steroid/antibiotic solutions. Distribution is national in Canada with recall classification RA-81839.

Medline Angiographic Kit Recall - Syringe Adaptor Unwinding Risk

Health Canada issued a Type I recall for Medline Namic Custom Angiographic Kits (catalog numbers 60700513, 60701152, 60700465) due to potential risk of the syringe rotating adaptor unwinding during use, which may cause procedural delays or death. Healthcare facilities must immediately stop using affected Namic RA Syringes and discard them. Recall identification number RA-81841.

Adjustable Navigated Surgical Drill Sheath

The USPTO published patent application US20260090814A1 for an adjustable navigated surgical drill sheath with augmented reality navigation capability. The invention includes a handle, main body, and adjustment arrangement allowing multiple specific drill depths. Fiducial markers enable AR navigation during surgical procedures. Medical device manufacturers may review for competitive intelligence.

Arthrex tissue collector for surgery, variable particle sizes, filters

The USPTO published Patent Application US20260090818A1 for Arthrex, Inc., disclosing a tissue collector device for surgical use featuring multiple filters with varying pore sizes to collect and sort tissue fragments by size. The application names inventors G. Joshua Karnes, Shane Noble, Christopher Bare, and Andrea Matuska, with a filing date of September 30, 2025.

Endoscopic stomach reconstruction method, fixation elements, gastric tissue

The USPTO published patent application US20260090819A1 by inventor Michael Murray disclosing methods and devices for endoscopically reconstructing gastric tissue. The invention includes passing an end effector through the esophagus into the stomach, grasping a fold from the lesser curvature, deploying fixation elements, and cutting to form a passageway. The application was filed on October 1, 2025.

Occlusive Implant with Shape Memory Fabric Technology

Boston Scientific Scimed filed patent application US20260090809A1 for an occlusive implant with shape memory fabric technology. The invention covers a framework that transitions between collapsed and expanded configurations, with an occlusive fabric made from shape memory polymer filaments that shift configurations upon stimulus exposure. Application No. 19341220 was published April 2, 2026.

Steerable Medical Shaft Control System

USPTO published patent application US20260090816A1 for a steerable medical device shaft control assembly. Invented by William B. Key et al., the invention features a handle with docking base and ball socket mechanism for controlling steerable shafts in medical devices. This is a routine patent publication with no immediate regulatory or compliance impact.

PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE

USPTO published patent application US20260091024A1 for substituted riluzole prodrug compositions useful for treating cancers including melanoma, breast cancer, brain cancer, and prostate cancer. The prodrugs are designed for oral administration with enhanced stability to hepatic metabolism, releasing riluzole in plasma via enzymatic or biophysical processes. Inventors include Jay Edward Wrobel, Allen B. Reitz, Jeffrey Claude Pelletier, Garry Robert Smith, and Haiyan Bian. Application No. 19064963 was filed February 27, 2025.

Pharmaceutical Composition for Treating Fatty Liver Disease

USPTO published Shionogi & Co., Ltd.'s patent application US20260091022A1 for a pharmaceutical composition treating fatty liver disease. The application was filed December 9, 2025, and published April 2, 2026, covering a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. CPC classifications are A61K 31/4184 and A61P 1/16.

Seaweed Polyphenol Antioxidant Extract System and Method

The USPTO published patent application US20260091326A1 by inventor Sabrena Mackenzie, disclosing a process for producing a high-quality polyphenol-containing antioxidant extract from seaweed biomass. The process yields residual biomass available for alginate and fucoidan production. The application (No. 19110368) was filed September 8, 2023 and classified under CPC codes B01D 11/0288 and A61K 36/03.

Gel-Chewable Dosage Form Patent Application

USPTO published patent application US20260091023A1 for a gel-chewable dosage form drug delivery system. Inventors Vipul Dave and Anurag Pandey disclose a formulation with multiple active pharmaceutical ingredients, where at least one is encapsulated in lipid material embedded in the gel base. The invention includes methods for treating diseases or disorders of the gastrointestinal tract.

TREM2 antibodies patent, neurodegenerative disease treatment, 2nd Apr

TREM2 antibodies patent, neurodegenerative disease treatment, 2nd Apr

Anti-CTLA-4 Antibodies for Treating Adenoid Cystic Carcinoma

The USPTO published patent application US20260092112A1 covering uses of anti-CTLA-4 antibodies for treating adenoid cystic carcinoma. Inventors Yang Liu and Pan Zheng filed Application No. 19112015 on September 15, 2023, with the application published April 2, 2026. The invention claims therapeutic applications of anti-CTLA-4 antibodies specifically for adenoid cystic carcinoma.

CD28/OX40 Bispecific Antibodies for Solid Organ Transplant Rejection Treatment

The USPTO published patent application US20260092113A1, filed by Bristol-Myers Squibb, covering methods for treating solid organ transplant rejection using CD28/OX40 bispecific antibodies. The application (No. 19237572) claims a multispecific binding protein with a VHH domain targeting CD28 and a VH/VL domain targeting OX40. Inventors include Rami Lissilaa, Benjamin Suratt, and Jessica Voss.

Treatment of Lung Cancer Using Anti-PD-1 Antibody Combination

The USPTO published Bristol-Myers Squibb Company's patent application (US20260092114A1) for a method of treating lung cancer using a combination of an anti-PD-1 antibody administered by infusion in under 60 minutes and optionally an anti-CTLA-4 antibody administered in under 90 minutes. The application was filed on September 29, 2025.

Anti-CTLA-4 antibodies with variant Fc regions

The USPTO published patent application US20260092115A1 for anti-CTLA-4 antibodies featuring variant Fc regions and methods of production and use. The application (No. 19407391) was filed December 3, 2025, by a team of 11 inventors including researchers from pharmaceutical companies. The invention relates to therapeutic antibodies modified to enhance effector functions through Fc region engineering.

B7H3/PDL1 Bispecific Antibody Cancer Therapeutic

The USPTO published patent application US20260092116A1 by DARTSBIO Pharmaceuticals Ltd. covering a B7H3/PDL1 bispecific antibody for cancer treatment. The invention comprises a monoclonal antibody targeting PDL1 linked to nano-antibodies targeting B7H3, designed to relieve T-cell inhibition while targeting tumor cells. The application was filed October 13, 2022, with six inventors.

Bladder Cancer Classification and Treatment Using Atezolizumab

The USPTO published patent application US20260092117A1 disclosing methods for classifying and treating bladder cancer (including locally advanced or metastatic urothelial cancer) using atezolizumab, a PD-1 axis binding antagonist. The application covers diagnostic methods, treatment regimens, compositions, kits, and articles of manufacture for bladder cancer classification and therapy. The application was filed on April 4, 2025.

Treatment of Cancer Using Anti-HLA-G/Anti-CD3 Bispecific Antibody and 4-1BB Agonist

The USPTO published patent application US20260092118A1 by Hoffmann-La Roche Inc., covering a method for treating cancer using an anti-HLA-G/anti-CD3 bispecific antibody in combination with a 4-1BB (CD137) agonist. The application (No. 19325175) was filed September 10, 2025, and lists Meher Majety, Carina Hage, and Johannes Sam as inventors. This publication represents an early-stage intellectual property filing for a bispecific antibody-based cancer therapy.

Multivalent FZD4, Wnt Co-receptor, and VEGF Binding Molecules

EyeBiotech Limited published US Patent Application US20260092125A1 for multivalent antibody binding molecules comprising FZD4 receptor binding, LRP5 co-receptor binding, and VEGF binding domains that activate the Wnt/β-catenin signaling pathway. The application covers the molecules, nucleic acids, vectors encoding them, and methods of use. Inventors include Paul E. Stephens, Michael John Davies, Yin Shan Eric Ng, Masahisa Handa, and Alexander V. Loktev. The application was filed September 4, 2025, and published April 2, 2026.

Anti-NRP2 Antibody Compositions and Methods for Treating NRP2-Associated Diseases

The USPTO published patent application US20260092122A1 for affinity-matured and humanized antibodies targeting human neuropilin-2 (NRP2) polypeptides. The application (No. 19293892, filed August 7, 2025) names six inventors and covers therapeutic compositions and methods for modulating NRP2 activity to treat NRP2-associated diseases, including cancer (A61P 35/04).

Governor Hochul Declares April Sexual Assault Awareness Month

Governor Hochul issued a proclamation declaring April 2026 as Sexual Assault Awareness Month in New York State. State landmarks including 1WTC, the Governor Mario M. Cuomo Bridge, and others will be illuminated in teal on April 1 and April 29. The FY27 Executive Budget proposes extending rape kit retention periods and legislation to prevent evidence destruction without survivor consent.